I-124 Codrituzumab

N/A

Report date: 2025/11/18 17:45:24

Base Information

Drug NameI-124 Codrituzumab
Drug Alias Name124I-Codrituzumab
ClassificationRadiation-emitting products > Nuclides > Iodine > 124IRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHoffmann-La Roche IncChugai Pharmaceutical Co LtdMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A